ALTIRIS THERAPEUTICS
Altiris Therapeutics develops and commercializes drugs to treat metastatic cancer. The company offers CXCR4 receptor, which acts as a mediator of cellular and chemical trafficking; and Emtriva, which is used for the treatment of HIV Infection. Altiris Therapeutics was founded in 2005 and is based in Atlanta, Georgia.
ALTIRIS THERAPEUTICS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2005-01-01
Address:
Atlanta, Georgia, United States
Country:
United States
Total Employee:
501+
Status:
Active
Contact:
(404) 537-4961
Total Funding:
46.34 M USD
Similar Organizations
Bone-Rad Therapeutics
Bone-Rad Therapeutics is a Delaware corporation whose objective is to develop and market brachytherapy bone cement to treat tumors in bone.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Targeted Cancer Therapeutics
Targeted Cancer Therapeutics develops therapies for treating cancer.
TransCardiac Therapeutics
TransCardiac Therapeutics develops technologies to facilitate access to the human heart.
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Current Advisors List
Current Employees Featured
Founder
Investors List
ATDC
ATDC investment in Venture Round - Altiris Therapeutics
ATDC
ATDC investment in Series C - Altiris Therapeutics
ATDC
ATDC investment in Series B - Altiris Therapeutics
Georgia Venture Partners
Georgia Venture Partners investment in Series B - Altiris Therapeutics
Centrosome Ventures
Centrosome Ventures investment in Series B - Altiris Therapeutics
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series B - Altiris Therapeutics
Talu Ventures
Talu Ventures investment in Series B - Altiris Therapeutics
H.I.G. Capital
H.I.G. Capital investment in Series B - Altiris Therapeutics
SR One
SR One investment in Series B - Altiris Therapeutics
MedImmune Ventures
MedImmune Ventures investment in Series B - Altiris Therapeutics
More informations about "Altiris Therapeutics"
Altiris Therapeutics - Crunchbase Company Profile & Funding
Altiris Therapeutics develops and commercializes drugs to treat metastatic cancer. The company offers CXCR4 receptor, which acts as a mediator of cellular and chemical trafficking; and โฆSee details»
Altiris Therapeutics, Inc.: Drug pipelines, Patents, Clinical trials ...
Jun 21, 2023ย ยท Explore Altiris Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, and 1 literature, Technology Platform:Small molecule drug, โฆSee details»
Altiris Therapeutics Inc - Company Profile and News
Company profile page for Altiris Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
Altiris Therapeutics - Company Profile - Tracxn
Altiris Therapeutics - CXCR4 receptor antagonist for solid tumors. This company is not active anymore. Raised a total funding of $37.5M over 2 rounds from 9 investors. Founded by Dennis โฆSee details»
Altiris Therapeutics, Inc.:Company Profile & Technical Research ...
Altiris Therapeutics, Inc. is a company that provides Drug, Pharmacy and Therapeutics, CXCR4 and more. Altiris Therapeutics, Inc. is headquartered in United States Georgia. Altiris โฆSee details»
Altiris Therapeutics - Funding, Financials, Valuation & Investors
Altiris Therapeutics develops and commercializes drugs to treat metastatic cancer.See details»
Altiris Therapeutics funding & investors - Tracxn
Nov 4, 2024ย ยท Altiris Therapeutics has raised a total funding of $37.5M over 2 rounds from 9 investors. Investors include Frazier Healthcare Partners, SR One and 7 others. Their latest โฆSee details»
Altiris Therapeutics - Updates, News, Events, Signals & Triggers
Altiris Therapeutics develops and commercializes drugs to treat metastatic cancer.See details»
Altiris Therapeutics - Products, Competitors, Financials, Employees ...
Developer of small molecule therapeutics for the treatment of aggressive and refractory metastatic cancers and inflammation. Use the CB Insights Platform to explore Altiris Therapeutics's full โฆSee details»
Altiris Therapeutics Inc. - BioCentury Company Profiles - BCIQ
Website: http://www.altiristherapeut... Historical deals and financings can be found by searching the organization's name in the BCIQ Deals and Financing Modules.See details»
Drug Discovery Companies | Emory University | Atlanta GA
Company Profile: Altiris Therapeutics, Inc. developed and commercialized orally administered small-molecule drug therapies. The company was developing drugs that inhibit CXCR4, a โฆSee details»
Altiris Therapeutics Stock Price, Funding, Valuation, Revenue ...
See Altiris Therapeutics funding rounds, investors, investments, exits and more. Evaluate their financials based on Altiris Therapeutics's post-money valuation and revenue.See details»
Patents Assigned to Altiris Therapeutics, Inc.
Nov 15, 2012ย ยท Applicant: ALTIRIS THERAPEUTICS, INC. Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts, solvates, tautomers, โฆSee details»
Altiris Therapeutics CEO, Founder, Key Executive Team, Board of ...
Explore {Altiris Therapeutics's key management people. Discover current leadership team members including founders, CEO, other executives and board directors.See details»
Altiris Therapeutics - Contacts, Employees, Board Members, โฆ
Altiris Therapeutics develops and commercializes drugs to treat metastatic cancer.See details»
ALT-1188: A New CXCR4 Antagonist In Development For โฆ
Nov 15, 2013ย ยท Methods: We tested four nonpeptide CXCR4 antagonists (ALT1188, 1187, 1128, and 1228) with low molecular weights and a novel and simple scaffold: an azacarbazole, โฆSee details»
Research programme: CXCR4 antagonists - Altiris Therapeutics
Nov 6, 2014ย ยท Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. Metastatix (now Altiris Therapeutics) was discovering and โฆSee details»
Q 122 - AdisInsight - Springer
Nov 29, 2022ย ยท Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.See details»
Altiris Therapeutics - Crunchbase
Altiris Therapeutics develops and commercializes drugs to treat metastatic cancer.See details»
ALT-1188: A New CXCR4 Antagonist In Development For
Nov 15, 2013ย ยท Methods: We tested four nonpeptide CXCR4 antagonists (ALT1188, 1187, 1128, and 1228) with low molecular weights and a novel and simple scaffold: an azacarbazole, โฆSee details»